Gamida Cell Ltd. Gains 50.89%

Gamida Cell Ltd. (GMDA:NASDAQ) soared at $1.69, representing a gain of 50.9%. On Tue, Apr 18, 2023, GMDA:NASDAQ touched a New 2-Week High of $1.69. The stock got featured on our News Catalysts scanner on Tue, Apr 18, 2023 at 03:05 PM in the 'BIOTECH' category. From Tue, Apr 04, 2023, the stock recorded 44.44% Up Days and 40.00% Green Days

About Gamida Cell Ltd. (GMDA:NASDAQ)

Gamida Cell Ltd is engaged in the development of cellular and immune therapeutics for cancer and rare genetic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma.